Further dollar pain ahead as safe-haven status crumbles: Morgan Stanley

Further dollar pain ahead as safe-haven status crumbles: Morgan Stanley
Source link

Further dollar pain ahead as safe-haven status crumbles: Morgan Stanley
Source link
The Four Legs MT4 Indicator is designed to spot changes in market direction using price action patterns and trend confirmation. It tracks key market swings, often referred to as legs to highlight phases of buying and selling pressure. Each leg represents a movement that shows where the market is gaining or losing momentum. This helps…
As shown on today’s XBR/USD chart, Brent crude oil prices have jumped (as indicated by the arrow) to a one-week high. This surge follows U.S. intelligence reports suggesting that Israel may be preparing to strike Iran’s nuclear facilities. Although CNN, citing officials, noted that it remains unclear whether Israeli leaders have made a final decision,…
Tariff Agenda Hits Currencies as Traders Await NFP! XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX” width=”0″ style=”display:none;visibility:hidden”> Source link
Eurozone PMI Manufacturing was finalized at 48.8 in December, down from November’s 49.6 and marking a nine-month low. Regional divergence remained pronounced. Greece (52.9) and Ireland (52.2) stayed in expansion, while the Netherlands held just above 50 at 51.1. France surprised on the upside at 50.7. However, weakness in the core was decisive, with Germany…
2025.01.21 2025.01.21 Gold Prices Boosted After Trump’s Inauguration. Forecast as of 21.01.2025 Dmitri Demidenkohttps://www.litefinance.org/blog/authors/dmitri-demidenko/ The previous trade war spurred XAUUSD quotes. Today, gold has a significant competitive advantage in the form of geopolitical factors. This provides the precious metal with a resilience that allows it to withstand strong headwinds. Let’s discuss these topics and make…
Investing.com — Boston Scientific (NYSE:) stock climbed over 1% in premarket trading Wednesday after the company raised its full-year earnings guidance, surpassing the consensus estimate. For the third quarter, the biotech firm reported earnings per share (EPS) of $0.63, surpassing the analyst estimate of $0.59. Revenue stood at $4.21 billion, also above the $4.04 billion…